Suppliers and packagers for generic pharmaceutical drug: glucagon

glucagon

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amphastar Pharms Inc	GLUCAGON	glucagon	INJECTABLE;INJECTION	208086	ANDA	Amphastar Pharmaceuticals, Inc.	0548-5850-00	1 KIT in 1 KIT (0548-5850-00) * 1 mL in 1 VIAL (0548-5905-00) * 1 mL in 1 SYRINGE (0548-5831-00)	2021-02-10
Amphastar Pharms Inc	GLUCAGON	glucagon	INJECTABLE;INJECTION	208086	ANDA	A-S Medication Solutions	50090-6550-0	1 KIT in 1 VIAL (50090-6550-0) / 1 KIT in 1 KIT * 1 mL in 1 VIAL (0548-5905-00) * 1 mL in 1 SYRINGE (0548-5831-00)	2021-02-10
Cipla	GLUCAGON	glucagon	INJECTABLE;INJECTION	218813	ANDA	Cipla USA Inc.	69097-027-50	1 KIT in 1 CARTON (69097-027-50) * 1 mL in 1 VIAL, GLASS (69097-028-32) * 1 mL in 1 SYRINGE, GLASS (69097-029-31)	2025-10-08
Cipla	GLUCAGON	glucagon	INJECTABLE;INJECTION	218813	ANDA	Sportpharm LLC	85766-043-01	1 KIT in 1 CARTON (85766-043-01) * 1 mL in 1 VIAL, GLASS (69097-028-32) * 1 mL in 1 SYRINGE, GLASS (69097-029-31)	2025-10-08
Lupin Ltd	GLUCAGON	glucagon	INJECTABLE;INJECTION	214457	ANDA	Lupin Pharmaceuticals, Inc.	70748-311-01	1 KIT in 1 CARTON (70748-311-01) * 1 mL in 1 VIAL (70748-309-01) * 1 mL in 1 SYRINGE (70748-310-01)	2025-08-04
Mylan Labs Ltd	GLUCAGON	glucagon	INJECTABLE;INJECTION	204468	ANDA	Mylan Pharmaceuticals Inc.	0378-8067-90	1 KIT in 1 KIT (0378-8067-90) * 1 mL in 1 VIAL (0378-8065-32) * 1 mL in 1 SYRINGE (0378-8066-32)	2025-02-26

Glucagon Supply Chain Analysis

Last updated: February 19, 2026

Glucagon's reliance on specific suppliers presents concentrated risks and opportunities within the pharmaceutical industry. The upstream production of glucagon, primarily through recombinant DNA technology, necessitates specialized manufacturers with expertise in fermentation, purification, and lyophilization. Key suppliers operate within a limited ecosystem, impacting availability, cost, and intellectual property considerations.

Who are the Primary Manufacturers of Glucagon API?

The active pharmaceutical ingredient (API) for glucagon is predominantly manufactured by a few specialized companies. These entities leverage advanced biotechnology to produce the peptide hormone.

• Eli Lilly and Company has historically been a major player, not only as a marketer of glucagon formulations but also as an integrated manufacturer of the API. Their internal capabilities for recombinant protein production are a significant factor in the global supply.
• Hospira, Inc. (now part of Pfizer) was another key supplier, particularly known for its sterile injectable products, including glucagon. Their manufacturing processes for both API and finished dosage forms were critical to the market.
• Emerging Biologics Manufacturers: While specific names are often proprietary or less publicly disclosed, the landscape is evolving. Contract Development and Manufacturing Organizations (CDMOs) with expertise in peptide synthesis and recombinant protein production are increasingly involved. These CDMOs offer services that can range from process development to large-scale commercial manufacturing. Identifying these specialized CDMOs is crucial for understanding the broader supply network and potential alternative sourcing.

The proprietary nature of API manufacturing, particularly for complex biologics like glucagon, means that publicly available lists of API suppliers are scarce. Companies typically secure these through direct contracts and long-term supply agreements. The barriers to entry for new glucagon API manufacturers are substantial, requiring significant capital investment in facilities compliant with Good Manufacturing Practices (GMP), specialized scientific expertise, and regulatory approvals.

What are the Key Technological Aspects of Glucagon Production?

The production of glucagon API is a complex biotechnological process.

• Recombinant DNA Technology: Glucagon is a peptide hormone. Its production typically involves inserting the gene for human glucagon into a host organism, such as Escherichia coli or yeast. This host organism then expresses the glucagon protein during fermentation.
  • Fermentation: Large-scale bioreactors are used to culture the genetically modified host cells under controlled conditions to maximize protein yield. This stage requires precise control of temperature, pH, nutrient supply, and oxygen levels.
  • Downstream Processing: Following fermentation, the glucagon protein must be extracted and purified from the host cells and culture medium. This involves a series of steps:
    • Cell Lysis: Breaking open the host cells to release the intracellular glucagon.
    • Initial Separation: Removing cellular debris and other contaminants.
    • Chromatography: Employing techniques such as ion-exchange chromatography, size-exclusion chromatography, and hydrophobic interaction chromatography to isolate glucagon from other proteins and impurities. The purity requirements for pharmaceutical APIs are exceptionally high.
    • Refolding (if applicable): If the glucagon is produced as an inclusion body, a refolding step is necessary to achieve its correct three-dimensional structure.
• Lyophilization (Freeze-Drying): Glucagon API is often supplied in a lyophilized form to enhance its stability for storage and transport. This process involves freezing the purified glucagon solution and then removing the ice as water vapor under vacuum, leaving a dry powder.
  • Stability: Lyophilization significantly extends the shelf life of the API, which is critical for pharmaceutical supply chains.
  • Reconstitution: The lyophilized API is reconstituted with a suitable sterile diluent before administration.

The specific host organism, fermentation conditions, and purification protocols are proprietary trade secrets for each manufacturer, contributing to their competitive advantage and influencing production costs.

What is the Global Supply Landscape for Glucagon Formulations?

The finished dosage forms of glucagon are marketed by several pharmaceutical companies, often relying on the aforementioned API manufacturers or their own internal API production.

• Eli Lilly and Company: Markets GlucaGen® HypoKit and other glucagon formulations globally. Lilly's integrated supply chain, from API to finished product, provides a degree of control.
• Novo Nordisk: While not a primary glucagon manufacturer, Novo Nordisk has been involved in the glucagon market through historical product lines or licensing agreements in specific regions.
• EMERGENT BioSolutions: Has been a significant player in the emergency preparedness market, including the supply of glucagon auto-injectors (e.g., as a component in military medical kits). Their manufacturing capabilities for auto-injectors are a specialized niche within the broader glucagon market.
• Oasis Pharmaceuticals (formerly LCG Lifesciences): Has developed and sought approval for generic glucagon nasal spray products. The development of alternative delivery methods and generic versions diversifies the supply landscape and introduces competition.
• Bausch Health Companies (formerly Valeant Pharmaceuticals): Has historically marketed glucagon products in certain territories.

The supply landscape is characterized by:

• Limited Competition in Injectable Form: For standard injectable glucagon, the number of major global suppliers remains relatively small.
• Emergence of Generic and Alternative Forms: The development of generic glucagon (e.g., nasal spray) by companies like Oasis Pharmaceuticals introduces new supply sources and potential price pressures. These generics must demonstrate bioequivalence to the reference products.
• Geographic Concentration: Manufacturing facilities for both API and finished products can be concentrated in specific regions (e.g., North America, Europe), creating logistical complexities and potential vulnerabilities to regional disruptions.
• Regulatory Hurdles: Obtaining and maintaining regulatory approval for glucagon products in different countries (e.g., FDA in the US, EMA in Europe) requires extensive data and compliance, acting as a barrier for new entrants.

What are the Regulatory Considerations for Glucagon Suppliers?

Suppliers of glucagon API and finished products are subject to stringent regulatory oversight.

• Good Manufacturing Practices (GMP): All facilities involved in the manufacturing, processing, packaging, and holding of glucagon API and finished drug products must adhere to current Good Manufacturing Practices (cGMP) as defined by regulatory authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes requirements for quality management systems, facility and equipment standards, personnel training, and process validation.
• Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the DMF in their own regulatory submissions without disclosing proprietary API information.
• Site Inspections: Regulatory agencies conduct routine inspections of manufacturing sites to ensure ongoing compliance with GMP. Non-compliance can lead to warning letters, import alerts, and product recalls, disrupting supply.
• Pharmacopeial Standards: Glucagon API and its formulated products must meet the specifications outlined in relevant pharmacopeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These standards define identity, purity, strength, and quality criteria.
• Post-Approval Changes: Any changes to the manufacturing process, formulation, or suppliers of critical components for an approved glucagon product must be reported to and often approved by regulatory authorities. This can involve significant lead times and validation efforts.

The rigorous regulatory environment means that qualifying and auditing new suppliers for glucagon API or finished products is a lengthy and resource-intensive process for pharmaceutical companies.

What are the Supply Chain Risks Associated with Glucagon?

The concentrated nature of glucagon manufacturing presents several key supply chain risks.

• Single-Source Dependence: If a pharmaceutical company relies on a single API supplier or a limited number of suppliers for a critical intermediate, any disruption at that supplier's facility (e.g., quality issues, natural disasters, geopolitical events, labor disputes, regulatory actions) can lead to a stock-out of the finished product.
• Technological Obsolescence or Process Challenges: Glucagon production, being a biotechnological process, can be susceptible to challenges in scaling up, maintaining consistent yields, or encountering unforeseen technical issues during manufacturing. The proprietary nature of these processes means that troubleshooting expertise may be confined to the original developer.
• Raw Material Availability: While glucagon itself is the focus, the production process relies on a secure supply of raw materials for fermentation media and purification reagents. Shortages or price volatility of these upstream components can impact glucagon API costs and availability.
• Logistical Vulnerabilities: The global nature of pharmaceutical supply chains means that glucagon API and finished products can be subject to transportation delays, customs issues, and temperature excursions during transit, particularly for temperature-sensitive biologics.
• Intellectual Property and Patent Cliffs: While the core glucagon molecule is well-established, patents related to specific manufacturing processes, formulations, or delivery devices can influence market exclusivity. The expiry of key patents can open the door for generics but may also be preceded by strategic moves from incumbent manufacturers to protect their market share.
• Geopolitical Instability: Reliance on manufacturing sites in regions prone to political unrest or trade disputes can introduce significant supply chain uncertainty.

What are the Opportunities for Diversifying the Glucagon Supply Chain?

Addressing the inherent risks creates opportunities for strategic supply chain management.

• Dual Sourcing Strategies: Pharmaceutical companies can mitigate single-source risks by qualifying and maintaining relationships with at least two independent API manufacturers. This requires significant investment in supplier audits, technical transfer, and maintaining inventory.
• Development of Generic and Biosimilar Alternatives: The successful development and market entry of generic glucagon products (e.g., nasal sprays) or potentially biosimilar versions (though glucagon's molecular size and complexity might lean more towards the generic definition for regulatory purposes in many jurisdictions) can increase competition and expand the supplier base. This requires robust bioequivalence studies.
• Contract Manufacturing Organization (CMO) Partnerships: Leveraging specialized CDMOs with proven expertise in peptide synthesis and recombinant protein manufacturing offers a pathway to diversify manufacturing without the capital investment of in-house facilities. Careful selection and robust contracts are critical.
• Technological Innovation in Manufacturing: Investment in and adoption of novel manufacturing technologies, such as continuous manufacturing or advanced cell culture techniques, could potentially improve yields, reduce costs, and enhance the robustness of glucagon production.
• Geographic Diversification of Manufacturing: Establishing or partnering with manufacturing sites in different geographic regions can reduce vulnerability to localized disruptions.
• Strategic Inventory Management: Implementing sophisticated inventory management systems, including safety stock strategies and proactive demand forecasting, can buffer against short-term supply disruptions.

Key Takeaways

• Glucagon API manufacturing is concentrated among a limited number of specialized biotechnology firms, often integrated with finished product marketers.
• Recombinant DNA technology and complex downstream purification processes are central to glucagon production, requiring significant technical expertise and capital investment.
• The global supply of finished glucagon formulations is dominated by a few key players, though the emergence of generic alternatives is beginning to diversify the market.
• Suppliers must adhere to strict GMP regulations, pharmacopeial standards, and undergo regular inspections by health authorities.
• Supply chain risks are significant, primarily stemming from single-source dependence, technical complexities, and logistical vulnerabilities.
• Opportunities for diversification lie in dual-sourcing, developing generics, partnering with CDMOs, and embracing manufacturing innovation.

Frequently Asked Questions

1. What is the primary method used to produce glucagon API today? Recombinant DNA technology, involving the expression of human glucagon in host organisms like E. coli or yeast, followed by extensive purification.

2. Are there significant barriers to entry for new glucagon API manufacturers? Yes, substantial barriers include high capital investment for GMP-compliant facilities, specialized biotechnological expertise, and the lengthy process of regulatory approval.

3. How does the regulatory environment impact glucagon supply? Strict GMP compliance, pharmacopeial standards, and regulatory inspections ensure quality but also create a long and complex pathway for new suppliers to enter the market and for existing ones to implement changes.

4. Can glucagon be produced using traditional chemical synthesis? While peptide synthesis is possible, recombinant methods are generally more cost-effective and scalable for producing glucagon in the quantities required for pharmaceutical applications.

5. What are the main challenges in managing the glucagon supply chain? Key challenges include ensuring consistent quality and availability from a limited number of API producers, managing global logistics for a potentially temperature-sensitive product, and mitigating risks associated with single-source dependencies.